Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Curve vs Zealthy

Curve
Graded #289

Higher grade

vs+15
Zealthy
Graded #496

Lower grade

The verdict

Curve takes it — 61.7/100 to 46.7/100.

Curve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Curve (Try Curve LLC) is a telehealth platform offering compounded semaglutide and tirzepatide, prescribed by Beluga Health providers licensed in all 50 states and dispensed by VialsRx, a US 503A…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCurve +31
57
26
Dose & formulationEven
64
64
Clinical oversightCurve +27
68
41
Labs & monitoringZealthy +1
52
53
FulfillmentCurve +31
97
66
Contract termsZealthy +21
20
41
Curve · left barZealthy · right bar

The numbers

MetricCurveZealthy
WeighScore61.7/10046.7/100
GradeCC
Scorecard rank#289#496
Semaglutide$175/mo (compounded)$286/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$225/mo (compounded)$351/mo (starting dose, plus a separate fee, compounded)
CoverageAll 50 states34 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Curve

Graded #289 · C

Strengths

  • Offers both compounded semaglutide and tirzepatide, with every dose priced the same so cost does not rise as you titrate up.
  • LegitScript-certified (seal #51079066) and names both its 503A compounding pharmacy, VialsRx, and its provider network, Beluga Health.
  • Transparent tiered pricing with a real month-to-month option; consultation, medication, and free expedited shipping included, no membership.
  • Available in all 50 states with same-day provider review; no insurance needed and HSA/FSA accepted.

Where it loses points

  • Very new (2026 launch) with a thin track record; the site still shows a Webflow template credit and a leftover Cora reference in its Terms.
  • The cheapest headline rates ($99 semaglutide / $135 tirzepatide) require a 12-month prepay; true month-to-month is $175 and $225.
  • Both product pages currently display an out-of-stock status, so availability may be inconsistent.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Zealthy

Graded #496 · C

Strengths

  • Serves 34 states — meaningful nationwide footprint
  • Asynchronous model removes friction for patients who don't want a video visit
  • Independent licensed prescribers retain full clinical authority

Where it loses points

  • Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
  • Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
  • Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
  • Recently rebranded to Gronk Inc. amid active enforcement
  • FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard